Overview of Dr. Mundi
Dr. Prabhjot Mundi is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and James J. Peters Veterans Affairs Medical Center. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is one of 379 doctors at New York-Presbyterian Hospital and one of 117 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 20 publications and over 500 citings.
Office
161 Fort Washington Ave
New York, NY 10032
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2013 - 2016
Boston University Medical CenterResidency, Internal Medicine, 2010 - 2013
State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
NY State Medical License 2013 - 2026
MA State Medical License 2010 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 12 citationsTargeting TRK: A fast-tracked application of precision oncology and future directions.Arsenije Kojadinovic, Bahar Laderian, Prabhjot S. Mundi
Critical Reviews in Oncology/hematology. 2021-08-10 - 185 citationsAKT in cancer: new molecular insights and advances in drug developmentPrabhjot S. Mundi, Jasgit C. Sachdev, Carolyn K. McCourt, Kevin Kalinsky
British Journal of Clinical Pharmacology. 2016-10-01 - 52 citationsPrecision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated LymphomasJennifer K. Lue, Sathyen A. Prabhu, Yuxuan Liu, Yulissa Gonzalez, Akanksha Verma
Clinical Cancer Research. 2019-09-01
Abstracts/Posters
- Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive LymphomasPrabhjot S. Mundi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other OncogenesPrabhjot S. Mundi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
